Biopharmas have been advancing in how they connect data and processes across clinical, regulatory, safety and quality. In 2026, the operational focus will shift to creating even greater flow, connected execution across teams, supported by a technology backbone that improves data transparency, traceability and inspection readiness as Europe’s regulatory expectations keep evolving. In parallel, AI will move from early capability augmentation to more generic AI that operates embedded in systems with compliance.

Below are five predictions for where life sciences are headed in 2026 that operate within clear guardrails.

Europe’s Regulatory Landscape Will Push Teams Toward Inspection-ready Execution by Design
In 2026, regulatory change in Europe will feel less like a series of one-off milestones and more like a steady operating reality. Clinical teams will be firmly in a CTIS-first world under the EU Clinical Trials Regulation, which continues to raise expectations for consistency across countries, faster coordination and complete, traceable documentation, alongside broader moves toward more structured submissions such as eCTD 4.0. As organisations settle into this mode, the pressure shifts from “getting it done” to “getting it right, every time” with fewer exceptions and less tolerance for local workarounds.

At the same time, ICH E6(R3) continues to move the industry toward a more explicit, risk-based approach to GCP. Sponsors will increasingly be expected to demonstrate how quality is designed into a study and how oversight is executed across partners, data sources and systems. That narrows the gap between operations and compliance. It also changes what “inspection readiness” means day to day. It is not a scramble at the end. It is a continuous state that depends on clear process ownership, consistent documentation and a reliable trail of decisions.